Pros | Beats FD returns for both 3Y & 5Y duration. | Larger AUM within category. Beats FD returns for both 3Y & 5Y duration. | ||
Cons | 5Y returns in the bottom 25% of the category. 3Y returns in the bottom 25% of the category. | 5Y returns in the bottom 25% of the category. |
INDMoney rank | 8/8 | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 6 Years | 12 Years | ||
Fund Size | 847 Cr | 8346 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹1000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 1.03% | 0.89% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 38 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.6%) Apollo Hospitals Enterprise Ltd (7.7%) Cipla Ltd (6.68%) Fortis Healthcare Ltd (4.56%) Lupin Ltd (4.55%) | Sun Pharmaceuticals Industries Ltd (12.67%) Divi's Laboratories Ltd (8.07%) Lupin Ltd (7.26%) Cipla Ltd (6.29%) Apollo Hospitals Enterprise Ltd (5.97%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (99.05%) Basic Materials (0.95%) | Health (100%) | ||
Equity % | 96.74% | 99.66% | ||
Debt % | - | - | ||
P/E | - | - | ||
P/B | - | - | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 0.64% | 1.6% | ||
3-Month Return | 1.41% | 2.52% | ||
6-Month Return | 5.21% | 3.79% | ||
1-Year Return | 4.64% | 4.72% | ||
3-Year Return | 22.57% | 22.83% | ||
5-Year Return | 16.84% | 18.02% |
Sharpe | - | - | ||
Alpha | - | - | ||
Beta | - | - | ||
Standard Deviation | - | - | ||
Information Ratio | - | - |
Description | Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Dhaval Shah | Sailesh Raj Bhan,Lokesh Maru,Divya Sharma,Kinjal Desai |